NCT01685151View on ClinicalTrials.gov

A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Bipolar Disorder
Interventions
DRUG

Ramelteon SL (Dose 1)

Ramelteon tablets for sublingual administration

DRUG

Ramelteon SL (Dose 2)

Ramelteon tablets for sublingual administration

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY